Peptide profile · Cognitive
Cerebrolysin
Porcine brain-derived neuropeptide preparation containing bioactive peptide fragments of neurotrophic factors, used clinically in over 40 countries for stroke recovery, traumatic brain injury, and cognitive impairment
Written & reviewed by Michael Carroll · Research, Peptide Initiative
Typical dose
20-30 mL
Half-life
Approximately 15-30 minutes (IV administration)
Bioavailability
~85-100% (intramuscular injection)
Molecular weight
Bioactive peptide components are all below 10 kDa (10,000 Da); the preparation contains a spectrum of peptide sizes
Evidence level
Moderate human trials
01 · Compound profile
Scientific & efficacy data
Molecular formula
Complex mixture — no single molecular formula (contains multiple peptide fragments and free amino acids derived from porcine brain proteins)
Primary benefits
Clinical trials show improved movement and thinking skills after stroke, with brain-protective effects that help damaged neurons survive and rebuild connections.
Over 30 years of clinical use shows modest improvements in memory and daily function for people with Alzheimer's, though results vary between patients.
Early research suggests it helps brain cells recover after trauma by mimicking your body's natural repair signals, reducing inflammation and cell death.
Multiple research institutions
Amino acid sequence
Complex mixture of peptide fragments derived from BDNF, GDNF, NGF, CNTF, IGF-1, IGF-2, and other neurotrophic factors — no single amino acid sequence02 · Dosing
How much do I take?
20-30 mL · once daily
Intramuscular: An injection into a muscle, usually the thigh, shoulder, or buttock.
Bioavailability High — well absorbed into the bloodstream from the muscle.
Best time to take
Morning administration is generally preferred to minimize potential for agitation or sleep disruption.
With food?
Administration is by injection and is independent of food intake. No fasting required.
If stacking
If combining Cerebrolysin with other peptides or supplements, space administrations by at least 15-30 minutes when possible. Consult with a healthcare provider before combining with prescription medications.
＋ Increase if
- +You've tolerated the current dose for the recommended period without significant side effects
- +Therapeutic goals haven't been met at the current dose level
- +Your healthcare provider recommends dose escalation based on your response
- +Lab work or clinical assessments support a higher dose
－ Decrease if
- −Side effects are bothersome or impacting daily life despite management strategies
- −You experience any signs of an adverse reaction
- −Lab results indicate the need for dose reduction
- −Your healthcare provider recommends a lower dose based on your response
✓ Signs of right dose
- ✓Therapeutic goals being met with minimal side effects
- ✓Stable and consistent response to treatment
- ✓Lab values or clinical markers trending in the right direction
- ✓Good tolerance with manageable or absent side effects
Dosing Calculator
Calculate Your Exact Dose
Step 1: Peptide Weight
Find the weight printed on your peptide vial label
Look here!
The peptide weight is printed on the label
Look here!
The weight is on the label
Select Weight
Look for a number followed by 'mg' on the vial label (e.g., 5mg, 10mg)
03 · Suitability
Is this right for me?
Best for post-stroke neurorecovery and rehabilitation support & cognitive support in alzheimer's disease and vascular dementia
Best for
Post-stroke neurorecovery and rehabilitation support
Cerebrolysin is particularly well-suited for individuals focused on post-stroke neurorecovery and rehabilitation support. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Cognitive support in Alzheimer's disease and vascular dementia
Cerebrolysin is particularly well-suited for individuals focused on cognitive support in alzheimer's disease and vascular dementia. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Traumatic brain injury recovery and neuroprotection
Cerebrolysin is particularly well-suited for individuals focused on traumatic brain injury recovery and neuroprotection. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Age-related cognitive decline and mild cognitive impairment
Cerebrolysin is particularly well-suited for individuals focused on age-related cognitive decline and mild cognitive impairment. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Consider alternatives if
Do not use if
Use with caution if
Not sure?
Compare Cerebrolysin with similar peptides to find the best fit for your goals.
04 · Administration
How do I use it?
Intravenous (IV) injection or infusion · Intramuscular (IM) injection
Reconstitution — what you need
Example
Add the recommended volume of bacteriostatic water to the Cerebrolysin vial. Gently swirl (do not shake) until the powder is fully dissolved. The resulting solution should be clear. Calculate your individual dose based on the concentration and your prescribed amount.
Your dose of Cerebrolysin is determined by your healthcare provider. Using an insulin syringe marked in units, draw up the exact amount prescribed. For example, if the reconstituted concentration is 1mg/mL and your dose is 0.5mg, draw up 0.5mL (50 units on an insulin syringe). Always double-check calculations before injection.
Route
Subcutaneous injection (into the fatty tissue just under the skin)—allows for consistent absorption and can be self-administered at home after proper training
Best sites
Technique
- 01Wash your hands thoroughly with soap and water before handling supplies
- 02Clean the injection site with an alcohol swab and let it air dry completely
- 03Pinch a fold of skin at the chosen injection site
- 04Insert the needle at a 45-90 degree angle (depending on needle length and body composition)
- 05Inject the medication slowly and steadily over 5-10 seconds
- 06Release the skin fold and remove the needle, applying gentle pressure with a clean swab
- 07Rotate injection sites to prevent tissue irritation or lipodystrophy
- 08Dispose of the needle safely in a sharps container—never recap or reuse needles
Storage · before reconstitution
Store Cerebrolysin in the refrigerator at 36-46°F (2-8°C) in its original packaging. Protect from light and moisture. Do not freeze. Check the expiration date before use. Some formulations may be stored at room temperature for limited periods—check your specific product labeling.
Storage · after reconstitution
Once reconstituted, Cerebrolysin should be kept refrigerated at 36-46°F (2-8°C) and used within the timeframe specified on your product labeling (typically 14-28 days). Label the vial with the reconstitution date. Do not use if the solution appears cloudy, discolored, or contains particles.
Signs of degradation
Sample daily schedule
05 · Safety
Is it safe?
6 common side effects · 2 serious
Cerebrolysin is an FDA-unregulated neuroprotective agent consisting of porcine brain-derived peptides and amino acids that has been used primarily in Eastern Europe and Asia. Safety data is limited to observational clinical use and small open-label trials rather than rigorous randomized controlled trials with formal safety monitoring. As a complex mixture of undefined peptide fragments from animal sources, batch consistency and sterility cannot be guaranteed without pharmaceutical manufacturing standards. Potential allergic reactions to porcine proteins and transmissible spongiform encephalopathy (TSE) risks from animal-derived components have not been adequately ruled out.
Evidence consists of observational clinical use spanning several decades in European and Asian markets, supplemented by small clinical trials (n<200) that are generally open-label or poorly controlled. No Phase 1 dose-escalation studies, formal toxicology assessments, or Phase 3 randomized trials have been conducted by Western regulatory standards. Published safety data is limited and primarily in non-English journals with methodological limitations.
Common side effects · experienced by some users
Less common
These typically resolve with continued use or dose adjustment.
Stop and seek help if
- ×Severe or worsening side effects that don't improve with dose adjustment or supportive care
- ×Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
- ×Your healthcare provider recommends discontinuation based on your clinical response
- ×Development of any new medical condition that may be contraindicated with Cerebrolysin
- ×Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
- ×Abnormal lab results or clinical markers that suggest adverse effects
Cerebrolysin should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.
With other peptides
- ✓BPC-157 — No known direct interaction with Cerebrolysin. BPC-157 is sometimes used for its gut-protective properties, which could theoretically help manage GI side effects.
With medications
- ✓Blood thinners (warfarin, heparin) — Monitor closely if combining with Cerebrolysin as interactions may affect bleeding risk or drug metabolism.
With supplements
- ✓Multivitamins — Generally safe to take alongside Cerebrolysin. Space doses apart if taking oral formulations to ensure optimal absorption.
- ✓Electrolyte supplements — Helpful if experiencing any GI side effects that could lead to dehydration. Safe to combine.
06 · Effectiveness
How do I know it's working?
Moderate human trials · first signs days 1-5
Evidence level
Moderate human trials
(Phase 1-2)
How it works
Cerebrolysin is a mixture of brain-derived peptides that act like growth factors for nerve cells. It helps nerve cells survive injury, grow new connections, and reduces inflammation in the brain. This makes it useful for recovery after stroke or brain injury.
Cerebrolysin contains bioactive peptide fragments that mimic the activity of neurotrophic factors (BDNF, GDNF, NGF, CNTF). These fragments activate Trk receptors and downstream signaling pathways including PI3K/AKT and MAPK/ERK cascades, promoting neuronal survival, dendritic branching, and synaptogenesis. The preparation reduces excitotoxicity by modulating glutamate receptor activity and intracellular calcium levels. It also polarizes microglia from the pro-inflammatory M1 phenotype to the neuroprotective M2 phenotype through toll-like receptor modulation, thereby reducing neuroinflammation. The low molecular weight peptides cross the blood-brain barrier, allowing direct CNS access. Additionally, Cerebrolysin upregulates VEGF expression to promote angiogenesis in ischemic regions, restoring cerebral blood flow.
What to expect
Days 1-5
What you might notice
- •Acute neuroprotective effects begin as bioactive peptides cross the blood-brain barrier and activate neurotrophic signaling pathways
- •In acute stroke or TBI settings, early neuroprotection against ongoing ischemic damage occurs
- •Some patients report improved alertness or reduced confusion
What's normal
- •Initial response to Cerebrolysin is beginning at the cellular level
- •Different individuals experience Cerebrolysin's onset at different rates
- •Transient systemic effects from initial Cerebrolysin exposure are common
What's next
- →Maintain consistent Cerebrolysin administration as prescribed
- →Document subjective effects and physical markers daily
- →Schedule a check-in with your provider about initial observations
Days 5-21
What you might notice
- •Neurorestorative processes are actively stimulated including neurogenesis, synaptogenesis, and angiogenesis in damaged brain regions
- •Measurable improvements in cognitive function, motor recovery, or speech may become apparent
- •This phase corresponds to the standard treatment course duration
What's normal
- •Cerebrolysin is achieving sufficient receptor engagement
- •Initial mechanism of Cerebrolysin is taking effect
- •Early transient effects from Cerebrolysin administration are resolving
What's next
- →Maintain consistent Cerebrolysin administration as prescribed
- →Document subjective effects and physical markers daily
- →Schedule a check-in with your provider about initial observations
Weeks 3-8
What you might notice
- •Therapeutic effects continue to develop and consolidate after the treatment course ends
- •The neurotrophic and neuroplastic changes initiated during treatment produce ongoing functional improvements
- •Clinical studies demonstrate that benefits persist and may continue to increase for weeks after the last injection
What's normal
- •Cerebrolysin is now achieving steady-state pharmacokinetics
- •Measurable changes aligned with Cerebrolysin's mechanism may appear
- •Initial adjustment effects typically resolve by this point
What's next
- →Maintain Cerebrolysin dosing exactly as established
- →Track progress toward intended outcomes in detail
- →Review lab work or biomarker changes with your healthcare team
Months 2-6+
What you might notice
- •Sustained improvements in cognitive function and neurological status can persist for months
- •For chronic conditions such as Alzheimer's disease, repeat treatment courses at 2-3 month intervals may be recommended to maintain and build upon therapeutic gains
- •Long-term studies show that repeated courses can produce cumulative benefits
What's normal
- •Full therapeutic effects of Cerebrolysin are well-characterized at this point
- •Maintenance of Cerebrolysin's therapeutic effects is typical
- •Tolerance patterns with Cerebrolysin are generally stable over months
What's next
- →Comprehensive assessment of Cerebrolysin efficacy should be conducted
- →Discuss long-term continuation, cycling, or protocol modifications
- →Continue regular monitoring of relevant biomarkers or symptoms
Signs it's working · Treatment Response
- ✓Improvement in the primary symptoms or condition being treated
- ✓Positive changes in relevant lab values or clinical markers
- ✓Consistent, stable response to Cerebrolysin over time
- ✓Reduction in symptom frequency or severity
Signs it's working · General Well-being
- ✓Improved energy levels and daily functioning
- ✓Better quality of life related to the treated condition
- ✓Manageable or absent side effects indicating good tolerance
- ✓Positive feedback from healthcare provider during check-ups
Not seeing results? Common reasons
- •Not at therapeutic dose yet—initial doses are for building tolerance, not maximum effect
- •Insufficient time at target dose—most compounds need several weeks to show full benefits
- •Inconsistent dosing schedule—regular, consistent use is crucial for optimal results
- •Individual variation in response—genetics, metabolism, and other factors affect outcomes
- •Underlying conditions or medications interfering with absorption or effectiveness
- •Improper storage leading to degraded product—always verify proper storage conditions
Key research
07 · Questions
Frequently asked
What exactly is Cerebrolysin made from?+
Cerebrolysin is produced by controlled enzymatic proteolysis (breakdown) of purified porcine (pig) brain proteins. The manufacturing process, developed by EVER Pharma in Austria, yields a standardized solution containing approximately 25% low molecular weight bioactive peptides and 75% free amino acids. The peptide fragments include active sequences derived from several key neurotrophic factors including BDNF, GDNF, NGF, CNTF, IGF-1, and IGF-2. Each milliliter contains 215.2 mg of Cerebrolysin concentrate in sterile aqueous solution.
Is Cerebrolysin available in the United States?+
No, Cerebrolysin is not FDA approved and is not commercially available in the United States. However, it is approved and widely used in over 40 countries across Europe, Asia, and Latin America for the treatment of stroke, traumatic brain injury, Alzheimer's disease, and vascular dementia. It has been in clinical use since the 1970s and has an established safety record in those markets.
How is Cerebrolysin administered?+
Cerebrolysin is administered exclusively by injection — either intramuscularly (IM) for doses up to 5 ml, or intravenously (IV) for larger doses. Doses up to 10 ml can be given as a slow IV injection, while doses above 10 ml must be diluted in physiological saline and administered as an IV infusion over 15-60 minutes. Administration should be performed by qualified healthcare professionals. Cerebrolysin is not available in oral form.
What conditions is Cerebrolysin used to treat?+
Cerebrolysin is approved in various countries for the treatment of ischemic stroke (20-50 ml/day), traumatic brain injury (20-50 ml/day), Alzheimer's disease (10-30 ml/day), vascular dementia, and age-related cognitive impairment. Additional clinical research has explored its use in subarachnoid hemorrhage, neonatal hypoxic-ischemic encephalopathy, Down syndrome, and other neurological conditions.
How long does a treatment course last?+
A standard treatment course consists of daily injections for 10-21 days. For acute conditions like stroke or traumatic brain injury, treatment may extend up to 30 days. For chronic neurodegenerative conditions such as Alzheimer's disease, treatment courses are typically repeated every 2-3 months, with a minimum of 4 courses per year recommended for sustained therapeutic benefit. Clinical studies show that repeated courses can produce cumulative cognitive improvements.
Can Cerebrolysin be combined with other Alzheimer's medications?+
Yes, clinical evidence supports the combination of Cerebrolysin with cholinesterase inhibitors such as donepezil (Aricept). Studies have shown that this combination can enhance and prolong the therapeutic benefits compared to either treatment alone, particularly in moderate to advanced Alzheimer's disease. Cerebrolysin may also be combined with memantine. However, any combination therapy should be managed by a qualified neurologist.
Is Cerebrolysin safe for individuals with pork allergies?+
No. Cerebrolysin is derived from porcine (pig) brain tissue and is contraindicated in individuals with known hypersensitivity to porcine-derived products. Patients with pork allergies or religious/dietary restrictions regarding pork products should not use this medication. An allergic reaction test or careful monitoring during the first administration may be advisable for patients with a history of allergies.
08 · Further reading
History & related research
History · since 1949
A porcine brain extract that regenerates damaged neurons and restores cognitive function across 50+ countries.
Cerebrolysin is a standardized porcine brain-derived peptide preparation containing 80% low-molecular-weight peptides and 20% free amino acids. Developed in 1949 by Austrian neuropsychiatrist Gerhart Harrer, it contains fragments of neurotrophic factors including BDNF, GDNF, NGF, and CNTF.
Read the full history of Cerebrolysin